MARKET

BBIO

BBIO

Bridgebio Pharma
NASDAQ
76.60
-2.08
-2.64%
After Hours: 76.60 0 0.00% 19:30 08/28 EDT
OPEN
79.99
PREV CLOSE
78.68
HIGH
80.55
LOW
76.34
VOLUME
1.92M
TURNOVER
--
52 WEEK HIGH
93.42
52 WEEK LOW
46.81
MARKET CAP
14.97B
P/E (TTM)
-21.4656
1D
5D
1M
3M
1Y
5Y
1D
Alnylam drops as AstraZeneca posts full trial results for failed heart drug
Seeking Alpha · 1d ago
BridgeBio Pharma (BBIO) Starts ASCEND ATTR Dosing In Bid To Show Cardiac Improvement
Simply Wall St · 1d ago
Why Is BridgeBio Pharma (BBIO) Presenting New Acoramidis Data At ESC 2026?
Simply Wall St · 3d ago
White House is said to announce drug pricing deals with biotechs
Seeking Alpha · 3d ago
BridgeBio Doses First Participation In ASCENT-ATTR Study
NASDAQ · 3d ago
BridgeBio Pharma doses first patient in ASCEND-ATTR trial
TipRanks · 3d ago
BridgeBio Pharma Doses First Patient In ASCEND-ATTR Trial To Evaluate Effects Of Acoramidis To Enhance Cardiac Structure, Function, And Amyloid Burden In Individuals With Transthyretin Amyloid Cardiomyopathy
Benzinga · 3d ago
BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum
NASDAQ · 4d ago
More
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

Webull offers BridgeBio Pharma Inc stock information, including NASDAQ: BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBIO stock methods without spending real money on the virtual paper trading platform.